文档介绍：安罗替尼联合恩度或顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床研究
 
 
郑文慧米虽才陈志明
[摘要] 目的观察安罗替尼联合恩度或顺铂胸腔灌注治疗NSCLC恶性胸腔积液的疗效及安全性。方法将2018年5月～2019年11月海沧医院肿瘤科收治的84例多线治疗后NSCLC伴胸腔积液患者，随机分为安罗替尼联合恩度胸腔灌注治疗组及安罗替尼联合顺铂胸腔灌注对照组。两组患者均口服安罗替尼，行胸穿置管引流胸水后，治疗组及对照组分别采用恩度45 mg胸腔灌注，或顺铂40 mg/m2胸腔灌注，每周2次，最多4次为1个疗程。比较两组患者的近期疗效、生活质量，治疗
1周、2周及3周后胸水VEGF水平及治疗期间毒副反应情况。结果 %，%（P<）。治疗组患者生活质量改善32例（%），高于对照组的20例（%）（P<）;治疗组治疗后1周、2周及3周胸水VEGF水平显著低于对照组;且白细胞减少、恶心呕吐、肝肾功能损害等并发症发生率也低于对照组（P
[关键词] 安罗替尼;恩度;非小細胞肺癌;胸腔积液
[]           [] B          [] 1673-9701（2020）13-0076-04
[Abstract] Objective To observe the efficacy and safety of anlotinib combined with endo or cisplatin pleural infusion in the treatment of NSCLC malignant pleural effusion. Methods 84 patients with NSCLC and pleural effusion after multi-line treatment at Haicang Hospital from May 2018 to November 2019 were randomly divided into anlotinib combined with Endo pleural infusion therapy group and anlotinib combined with cisplatin pleural infusion control group. Patients in both groups were treated with anlotinib orally. After the pleural fluid was drained by thoracentesis， the treatment group and the control group were treated with Endo 45 mg pleural infusion， or cisplatin 40 mg/m2 pleural infusion， twice a week， up to four times as one course. The short-term efficacy， quality of life， VEGF levels in pleural fluid after 1 week， 2 weeks， and 3 weeks of treatment， and the side effects during the treatment were compared between the two groups. Results The OOR in the short-term efficacy of the treatment group was %
， which was higher than that（%） of the control group（P
[Key words] Anlotinib; Endo; Non-small cell lung cancer; Pleural effusion
恶性胸腔积液是晚期非小细胞肺癌（NSCLC）的一種并发症，大量胸腔积液会影响患者的呼吸和循环功能，若不能及时控制病情，会增加死亡风险[1]，是临床急需处理的肿瘤伴随症状之一。安罗替尼是一种新型抗肿瘤药物，在抗肿瘤血管生成和抑制肿瘤生长方面效果显著，具有较好的特异性及安全性[2]。2018年5月8日被cFDA批准用于肺癌的三线及以上治疗，且被中国临床肿瘤学会（Chinese society of clinical oncology，CSCO）纳入指南使用[3]。本研究通过随机分组的研究，对比了安罗替尼联合使用恩度与其联合使用顺